Annuncio • Aug 31
ReNeuron Group Admission to Trading on AIM to Be Cancelled with Effect from 2 September 2024 ReNeuron Group plc notified of the cancellation of the Company's ordinary shares ("Ordinary Shares") from trading on AIM. Further to the announcement on 2 August 2024 (the "Announcement"), Stephen Cork and Mark Smith of Cork Gully LLP (the "Joint Administrators"), have remained in discussions with the ReNeuron's main creditors to seek to clarify the liabilities of the Company and ascertain the Company's financial solvency in light of its current cash resources. The Joint Administrators anticipate being able to resolve matters such that the Company can exit Administration on a going concern basis in due course. However, this will only occur when the necessary legal documentation has been agreed and the Joint Administrators are working with creditors on this basis. In light of the above, as the Joint Administrators and the Board of ReNeuron no longer consider that there is a realistic possibility that the Company could raise sufficient funds to enable the Company to exit the Administration Process with sufficient working capital that would permit the restoration of trading on AIM on acceptable terms, notwithstanding the ongoing creditor discussions. Therefore,pursuant to Rule 41 of the AIM Rules, and with the ordinary shares of the Company having been suspended for more than six months, the Company's admission to trading on AIM will be cancelled with effect from 7.00 a.m. on 2 September 2024 ("Cancellation"). Annuncio • Apr 17
ReNeuron Group plc Announces Resignation of John Hawkins as Chief Financial Officer, Effect from 7 May 2024 ReNeuron Group plc announced that John Hawkins will be stepping down as Chief Financial Officer of the Company with effect from 7 May 2024, in order to pursue other opportunities. Notwithstanding his departure, John will continue to provide support to the Company during the ongoing administration process. Annuncio • Jan 30
ReNeuron Group plc Provides Group Earnings Guidance for the Second Half and Full Year 2024 ReNeuron Group plc provided group earnings guidance for the second half and full year 2024. The Board continues to expect the Group to deliver a stronger performance in the second half than the first.Albeit the weaker regional economic environment means that the Group expects to deliver full year results below market expectations. New Risk • Nov 10
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: UK£5.1m Forecast net loss in 1 year: UK£1.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£5.3m free cash flow). Share price has been highly volatile over the past 3 months (1,168% average daily change). Revenue is less than US$1m (UK£249k revenue, or US$304k). Market cap is less than US$10m (€3.33m market cap, or US$3.55m). Minor Risk Currently unprofitable and not forecast to become profitable next year (UK£1.4m net loss next year). Annuncio • Oct 27
ReNeuron Group plc to Report First Half, 2024 Results on Nov 09, 2023 ReNeuron Group plc announced that they will report first half, 2024 results on Nov 09, 2023 Annuncio • Jul 25
ReNeuron Group plc, Annual General Meeting, Aug 22, 2023 ReNeuron Group plc, Annual General Meeting, Aug 22, 2023, at 08:30 Coordinated Universal Time. Location: at the offices of Covington & Burling LLP, Level 54, 22 Bishopsgate London United Kingdom Reported Earnings • May 26
Full year 2023 earnings released: UK£0.095 loss per share (vs UK£0.17 loss in FY 2022) Full year 2023 results: UK£0.095 loss per share (improved from UK£0.17 loss in FY 2022). Net loss: UK£5.41m (loss narrowed 44% from FY 2022). Annuncio • May 19
ReNeuron Group plc to Report Q4, 2023 Results on May 25, 2023 ReNeuron Group plc announced that they will report Q4, 2023 results on May 25, 2023 Board Change • Apr 20
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Director Mike Owen is the most experienced director on the board, commencing their role in 2015. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Dec 03
First half 2023 earnings released: UK£0.056 loss per share (vs UK£0.092 loss in 1H 2022) First half 2023 results: UK£0.056 loss per share (improved from UK£0.092 loss in 1H 2022). Net loss: UK£3.18m (loss narrowed 39% from 1H 2022). Revenue is forecast to grow 5.2% p.a. on average during the next 2 years, compared to a 26% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 independent directors. 4 non-independent directors. Senior Independent Non-Executive Director Barbara Staehelin was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Board Change • Sep 20
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 independent directors. 4 non-independent directors. Senior Independent Non-Executive Director Barbara Staehelin was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Aug 18
Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021) Full year 2022 results: UK£0.17 loss per share (up from UK£0.29 loss in FY 2021). Net loss: UK£9.69m (loss narrowed 15% from FY 2021). Over the next year, revenue is forecast to grow 70%, compared to a 11% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings. Annuncio • Aug 17
ReNeuron Group plc, Annual General Meeting, Sep 09, 2022 ReNeuron Group plc, Annual General Meeting, Sep 09, 2022, at 08:30 Coordinated Universal Time. Location: Covington and Burling LLP Level 54 22 London Greater London United Kingdom Agenda: To receive and adopt the Company's Annual Report and Accounts for the financial year ended 31 March 2022 and the Directors' Report, and the Independent Auditors' Report on those accounts; to reappoint PricewaterhouseCoopers LLP as auditors of the Company; to reappoint as a Director Catherine Isted; to reappoint as a Director Martin Walton; to reappoint as a Director Dr. Mike Owen; and to transact other matters. Annuncio • Aug 01
ReNeuron Group plc Announces Appointment of Catherine Isted as Chief Executive Officer, Effective 1 September 2022 ReNeuron Group plc announced the appointment of Catherine Isted, ACMA, as Chief Executive Officer, effective 1 September 2022. Ms. Isted joined the ReNeuron Board as Chief Financial Officer in October 2021. Following the departure of the former CEO in February this year, Ms. Isted has worked closely with the Executive Management team, led by Iain Ross, to refocus the business around the Group's differentiated exosomes delivery platform.Ms. Isted is an experienced strategic finance professional and chartered management accountant with c.25 years' experience across the Healthcare industry. This includes 12 years at partner level in two leading Healthcare banking teams undertaking multiple Initial Public Offerings and follow-on fundraisings. Within the Healthcare industry, prior to joining ReNeuron, Ms. Isted has also held various in-house financial and strategic roles spanning Corporate Development, Investor Relations and Financial Planning and Analysis. Ms. Isted joined ReNeuron from Oxford Biomedica plc, a global leading cell and gene therapy company, where she was instrumental in raising in excess of £110 million and supporting potential board level strategic opportunities. She has also held senior research analyst and equity sales positions in the Healthcare teams at Morgan Stanley, ABN AMRO, Nomura and Peel Hunt. Ms. Isted holds a 1st Class chemistry degree along with experience as a bench scientist, before moving into finance and training as an accountant at Merck. Reported Earnings • Jul 05
Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021) Full year 2022 results: UK£0.17 loss per share (up from UK£0.29 loss in FY 2021). Net loss: UK£9.69m (loss narrowed 15% from FY 2021). Over the next year, revenue is forecast to grow 92%, compared to a 29% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. Annuncio • Jun 21
ReNeuron Group plc to Report Fiscal Year 2022 Results on Jul 04, 2022 ReNeuron Group plc announced that they will report fiscal year 2022 results on Jul 04, 2022 Annuncio • Jun 11
ReNeuron Group plc, Annual General Meeting, Jul 14, 2022 ReNeuron Group plc, Annual General Meeting, Jul 14, 2022, at 10:00 Coordinated Universal Time. Location: offices of Ashurst LLP, The London Fruit & Wool Exchange, 1 Duval Square, London E1 6PW London United Kingdom Annuncio • Feb 12
ReNeuron Group plc Announces CEO Changes, Effective 28 February 2022 ReNeuron Group plc announced that Olav Hellebø is standing down as CEO of the Company and will leave the Company on 28 February 2022. With immediate effect Iain Ross, Chairman, supported by Catherine Isted, CFO and the leadership team, will assume responsibility for the running of the business as the Company transitions to focus primarily on the development of its Exosome Technology Platform. Annuncio • Feb 11
ReNeuron Group plc Announces Leaving of Olav Hellebø as Executive Director ReNeuron Group plc announced that Olav Hellebø is standing down as executive director of the Company and will leave the Company on 28 February 2022. With immediate effect Iain Ross, Chairman, supported by Catherine Isted, CFO and the leadership team, will assume responsibility for the running of the business as the Company transitions to focus primarily on the development of its Exosome Technology Platform. Reported Earnings • Dec 02
First half 2022 earnings: EPS in line with expectations, revenues disappoint First half 2022 results: UK£0.092 loss per share (up from UK£0.22 loss in 1H 2021). Net loss: UK£5.23m (loss narrowed 26% from 1H 2021). Revenue missed analyst estimates by 48%. Over the next year, revenue is forecast to grow 55%, compared to a 80% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 22% per year. Recent Insider Transactions • Oct 22
Board Member recently bought €59k worth of stock On the 20th of October, Barbara Staehelin bought around 43k shares on-market at roughly €1.37 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Reported Earnings • Aug 22
Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020) Full year 2021 results: Net loss: UK£11.3m (flat on FY 2020). Products in clinical trials Phase II: 2 Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 9% per year. Reported Earnings • Jul 09
Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020) Full year 2021 results: Net loss: UK£11.3m (flat on FY 2020). Products in clinical trials Phase II: 2 Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Jan 08
New 90-day high: €1.16 The company is up 15% from its price of €1.01 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is flat over the same period. Is New 90 Day High Low • Dec 16
New 90-day low: €0.80 The company is down 12% from its price of €0.91 on 17 September 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 9.0% over the same period. Reported Earnings • Nov 26
First half 2021 earnings released: UK£0.22 loss per share First half 2021 results: Net loss: UK£7.09m (loss widened 82% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Nov 24
New 90-day low: €0.85 The company is down 24% from its price of €1.12 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Annuncio • Oct 03
ReNeuron Group plc to Report First Half, 2021 Results on Nov 10, 2020 ReNeuron Group plc announced that they will report first half, 2021 results on Nov 10, 2020 Annuncio • Aug 25
ReNeuron Group plc Auditor Raises 'Going Concern' Doubt ReNeuron Group plc filed its Annual on Aug 19, 2020 for the period ending Mar 31, 2020. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern. 
